Evidence map›Paper›PMID 32171575›Full record

ArticleVaccine2020

The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission.

Sarah M Bartsch, Owen J Stokes-Cawley, Pierre Buekens, Lindsey Asti, Maria Elena Bottazzi, Ulrich Strych, Patrick T Wedlock, Elizabeth A Mitgang, Sheba Meymandi, Jorge Abelardo Falcon-Lezama and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Vaccines against chronicExpert review of vaccines · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Sarah M BartschPublic Health Informatics, Computational, and Operations Research (PHICOR), City University of New York, 55 W 125th Street, New York City, NY 10027, USA.
Owen J Stokes-CawleyPublic Health Informatics, Computational, and Operations Research (PHICOR), City University of New York, 55 W 125th Street, New York City, NY 10027, USA.
Pierre BuekensDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA.
Lindsey AstiPublic Health Informatics, Computational, and Operations Research (PHICOR), City University of New York, 55 W 125th Street, New York City, NY 10027, USA.
Maria Elena BottazziNational School of Tropical Medicine and Departments of Pediatrics and Molecular Virology & Microbiology, Baylor College of Medicine, One Baylor Plaza, BCM113 Houston, TX 77030, USA.
Ulrich StrychNational School of Tropical Medicine and Departments of Pediatrics and Molecular Virology & Microbiology, Baylor College of Medicine, One Baylor Plaza, BCM113 Houston, TX 77030, USA.
Patrick T WedlockPublic Health Informatics, Computational, and Operations Research (PHICOR), City University of New York, 55 W 125th Street, New York City, NY 10027, USA.
Elizabeth A MitgangPublic Health Informatics, Computational, and Operations Research (PHICOR), City University of New York, 55 W 125th Street, New York City, NY 10027, USA.
Sheba MeymandiCenter of Excellence for Chagas Disease at Olive View-UCLA Medical Center, 14445 Olive View Drive, Sylmar, CA 91342, USA.
Jorge Abelardo Falcon-LezamaCarlos Slim Foundation, Lago Zurich 245, Piso 20. Ampliación Granada, Del. Miguel Hidalgo, C.P. 11529 Ciudad de México, Mexico.
Peter J HotezNational School of Tropical Medicine and Departments of Pediatrics and Molecular Virology & Microbiology, Baylor College of Medicine, One Baylor Plaza, BCM113 Houston, TX 77030, USA.
Bruce Y LeePublic Health Informatics, Computational, and Operations Research (PHICOR), City University of New York, 55 W 125th Street, New York City, NY 10027, USA. Electronic address: bruceleemdmba@gmail.com.
City University of New York · USBaylor College of Medicine · USOlive View-UCLA Medical Center · USTulane University · US

Funding

MULTILEVEL SYSTEMS-ORIENTED CHILDHOOD OBESITY STUDY IN CHINAU54HD070725 · NICHD · JOHNS HOPKINS UNIVERSITY · PI CURRIERO, FRANK · 2011 to 2016
$15.9M
Early Life Determinants of Obesity in U.S. Urban Low Income Minority Birth CohortR01HD086013 · NICHD · JOHNS HOPKINS UNIVERSITY · PI LEE, BRUCE Y, WANG, XIAOBIN · 2016 to 2020
$3.3M
Virtual Population Obesity Prevention (VPOP) Labs: Computational, Multi-Scale Models for Obesity SolutionsU01HD086861 · NICHD · JOHNS HOPKINS UNIVERSITY · PI LEE, BRUCE Y · 2015 to 2019
$2.8M
Regional Healthcare Ecosystem Analyst for Healthcare Associated InfectionsR01HS023317 · AHRQ · JOHNS HOPKINS UNIVERSITY · PI LEE, BRUCE Y · 2014 to 2014
$2.4M
AHRQ HHS R01 HS023317NICHD NIH HHS R01 HD086013NICHD NIH HHS U01 HD086861NICHD NIH HHS U54 HD070725
6 · The paper itself

Abstract

backgroundCurrently, there are no solutions to prevent congenital transmission of Chagas disease during pregnancy, which affects 1-40% of pregnant women in Latin America and is associated with a 5% transmission risk. With therapeutic vaccines under development, now is the right time to determine the economic value of such a vaccine to prevent congenital transmission.

methodsWe developed a computational decision model that represented the clinical outcomes and diagnostic testing strategies for an infant born to a Chagas-positive woman in Mexico and evaluated the impact of vaccination.

resultsCompared to no vaccination, a 25% efficacious vaccine averted 125 [95% uncertainty interval (UI): 122-128] congenital cases, 1.9 (95% UI: 1.6-2.2) infant deaths, and 78 (95% UI: 66-91) DALYs per 10,000 infected pregnant women; a 50% efficacious vaccine averted 251 (95% UI: 248-254) cases, 3.8 (95% UI: 3.6-4.2) deaths, and 160 (95% UI: 148-171) DALYs; and a 75% efficacious vaccine averted 376 (95% UI: 374-378) cases, 5.8 (95% UI: 5.5-6.1) deaths, and 238 (95% UI: 227-249) DALYs. A 25% efficacious vaccine was cost-effective (incremental cost-effectiveness ratio <3× Mexico's gross domestic product per capita, <$29,698/DALY averted) when the vaccine cost ≤$240 and ≤$310 and cost-saving when ≤$10 and ≤$80 from the third-party payer and societal perspectives, respectively. A 50% efficacious vaccine was cost-effective when costing ≤$490 and ≤$615 and cost-saving when ≤$25 and ≤$160, from the third-party payer and societal perspectives, respectively. A 75% efficacious vaccine was cost-effective when ≤$720 and ≤$930 and cost-saving when ≤$40 and ≤$250 from the third-party payer and societal perspectives, respectively. Additionally, 13-42 fewer infants progressed to chronic disease, saving $0.41-$1.21 million to society.

conclusionWe delineated the thresholds at which therapeutic vaccination of Chagas-positive pregnant women would be cost-effective and cost-saving, providing economic guidance for decision-makers to consider when developing and bringing such a vaccine to market.

Indexed as

Chagas DiseaseVaccinesCost-Benefit AnalysisFemaleHumansInfantLatin AmericaMexicoPregnancyPregnant PeopleVaccinationVaccinesChagas diseaseCongenital transmissionEconomicsPregnancyVaccine

Identifiers

PMID32171575
PMCPMC9009251
OpenAlexW3012556644

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.